Acquisition of Japanese development and commercialization rights for JX09 and preparations for a Phase I clinical trial
First written in FY2024-Q3. 3 of 6 entries say "Restated". Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1SoftenedAnnual report
「No significant safety or tolerability concerns were identified in the clinical trial. CORXEL is placing further development of JX09 on hold for strategic reasons.」
The Australian Phase I trial of JX09 was completed without significant safety or tolerability concerns, but CORXEL placed further development on hold for strategic reasons, materially weakening the plan to participate in global development through a Japanese trial. - FY2026-H1RestatedAnnual report
「CORXEL is currently conducting a Phase I clinical trial in Australia, and the Company is considering a plan to participate in the global trial by conducting a clinical trial in Japan.」
The Company reiterated the Australian Phase I trial led by CORXEL and its consideration of participating in the global trial through a Japanese trial. - FY2025RestatedAnnual report
「CORXEL is currently conducting a Phase I clinical trial in Australia, and the Company is considering a plan to participate in the global trial by conducting a clinical trial in Japan.」
The Company reiterated that CORXEL is conducting the Australian Phase I trial and that it is considering participating through a Japanese trial. - FY2025-H1RestatedAnnual report
「JIXING is currently conducting a Phase I clinical trial in Australia, and the Company is considering a plan to participate in the global trial by conducting a clinical trial in Japan.」
The Company reiterated the Australian Phase I trial and consideration of participating in the global trial through a Japanese study. - FY2025-Q1AdvancedAnnual report
「JIXING is currently conducting a Phase I clinical trial in Australia, and the Company is considering a plan to participate in the global trial by conducting a clinical trial in Japan.」
JX09 advanced to an ongoing Phase I trial in Australia and consideration of a plan for the Company to participate in the global trial through a Japanese trial. - FY2024-Q3First statedAnnual report
「The Company obtained from JIXING HK a royalty-free exclusive license for JX09 in Japan and entered into a binding basic agreement under which JIXING will bear 75% of the Company’s development costs in Japan, capped at $5 million, as part of JIXING’s global development of JX09. The parties will continue detailed discussions toward a definitive agreement. JX09 is an oral small-molecule aldosterone synthase inhibitor being developed by JIXING for treatment-resistant or uncontrolled hypertension, with a Phase I clinical trial scheduled to begin in the first half of 2024.」
The Company obtained a royalty-free exclusive Japanese license for JX09 and signed a basic agreement under which JIXING will bear up to 75% of Japanese development costs, subject to a cap. Phase I was planned to begin in the first half of 2024.